(282 days)
The Venous Softbag Reservoirs are indicated for use in extracorporeal circuits during cardiopulmonary bypass procedures in the field of open-heart-surgery. The utilization period of this device is restricted to six hours. Blood contact longer than 6 hours is not recommended. Application and use of the softbag reservoir is in the sole responsibility of the respective physician.
The Venous Softbag Reservoir is used in extracorporeal circuits during cardiopulmonary bypass surgery and serves as container for a certain blood volume. It consists of plastic foils which are welded together and between which tubes of different diameters and a polyester mesh are sandwiched. The polyester mesh serves for an improved air removal. Application duration: The utilization period of this device is restricted to six hours. The softbag reservoir is delivered sterile and is determined for single use only.
The group of Venous Softbag Reservoirs consists of a variety of models which differ in size (filling volume) and in the port sizes. The filling volumes of the reservoirs range from 650 ml to 1900 ml depending on the model and the ports are either 3/8" or ½" in size.
The provided document is a 510(k) summary for a medical device (Venous Softbag Reservoirs with Softline Coating) seeking market clearance from the FDA. This type of submission focuses on demonstrating substantial equivalence to a predicate device, rather than proving that the device meets specific acceptance criteria through extensive clinical studies as one might find for novel or high-risk devices.
Therefore, the document does not contain the detailed information requested about acceptance criteria, specific study designs (like multi-reader multi-case studies), sample sizes for test sets or training sets, expert qualifications for ground truth establishment, or effect sizes for human readers with AI assistance. This is because the regulatory pathway for this specific device (a Class II device demonstrating substantial equivalence) relies more on bench testing, biocompatibility, and sterility data to show it performs as intended and is as safe and effective as a legally marketed predicate device.
However, I can extract the information that is present:
1. A table of acceptance criteria and the reported device performance:
The document describes the areas tested and evaluated to demonstrate substantial equivalence, implying these areas represent the "acceptance criteria" for the device to be considered equivalent to the predicate. The "reported device performance" is essentially that the device was found to be substantially equivalent based on these evaluations.
| Acceptance Criteria (Areas Tested/Evaluated) | Reported Device Performance |
|---|---|
| Integrity | Meets criteria (implied by conclusion of substantial equivalence) |
| Performance | Meets criteria (implied by conclusion of substantial equivalence) |
| Biocompatibility | Meets criteria (implied by conclusion of substantial equivalence) |
| Sterility | Meets criteria (implied by conclusion of substantial equivalence) |
Notes on Acceptance Criteria and Performance:
- Specific quantitative values are not provided in this summary. For example, it doesn't state "integrity passed if burst pressure > X psi." The "performance" assessment refers to the device functioning as intended for its specified use in extracorporeal circuits, likely validated through bench testing, but the specifics are not detailed.
- The overall "reported device performance" is the conclusion that "The data given demonstrate that the Venous Softbag Reservoirs with Softline Coating are substantially equivalent to the named predicate devices."
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective):
- Sample Size for Test Set: This information is not provided in the document. The submission implies bench testing for integrity, performance, biocompatibility, and sterility, but does not specify the number of units tested for each.
- Data Provenance: This information is not provided. Given the manufacturer is based in Germany, the testing may have occurred there, but this is not explicitly stated. The nature of these tests (integrity, performance, biocompatibility, sterility) typically involves laboratory or bench testing rather than clinical data, so the concepts of retrospective/prospective human data provenance are not directly applicable here.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience):
- This information is not applicable/not provided. The assessment of this device for substantial equivalence primarily relies on technical specifications, material properties, and bench testing, not expert interpretation of diagnostic images or clinical outcomes that would require ground truth establishment by medical experts in the way requested.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:
- This information is not applicable/not provided. Adjudication methods are typically used in clinical studies or evaluations involving human interpretation where disagreements need to be resolved. This document pertains to a 510(k) submission for a device component, where such methods are not relevant.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- This information is not applicable/not provided. An MRMC study is relevant for diagnostic imaging devices often involving AI algorithms that assist human readers. This device is a passive component in a cardiopulmonary bypass circuit and does not involve AI or human "readers" in that context.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- This information is not applicable/not provided. This device is not an algorithm and does not perform a standalone diagnostic function.
7. The type of ground truth used (expert concensus, pathology, outcomes data, etc):
- Type of Ground Truth: The "ground truth" for this device's evaluation would be based on predefined engineering specifications, material standards, and biological compatibility requirements rather than expert consensus on clinical cases, pathology, or outcomes data. For example, "integrity" might be assessed against a standard burst pressure, "biocompatibility" against ISO 10993 standards, and "sterility" against standard sterilization assurance levels. The specific metrics are not detailed in this summary.
8. The sample size for the training set:
- This information is not applicable/not provided. This device is not an AI/ML algorithm that requires a training set.
9. How the ground truth for the training set was established:
- This information is not applicable/not provided. As above, this device is not an AI/ML algorithm that requires a training set or ground truth established in that manner.
{0}------------------------------------------------
DEC 2 3 2009
MAQUET
510(k) Summary
[as required by 21 CFR 807.92(c)]
| Submitter | MAQUET Cardiopulmonary AGHechinger Strasse 3872145 HirrlingenGermany | |
|---|---|---|
| Contact Person | Katrin Schwenkglenks |
Katrin Schwenkglenks Phone: 011 49 7478 921 151 Fax: 011 49 7478 921 400
Venous Reservoir Bag
Date Prepared March 12, 2009
Device Trade Name
Common/Usual Name
Classification Names
Reservoir, Blood, Cardiopulmonary Bypass (CFR 870.4400, product code : DTN)
Venous Softbag Reservoirs with Softline Coating
Legally Marketed Devices Jostra Venous Softbag Reservoirs with and without Safeline Coating (K070605), Adult Quadrox-i Microporous Membrane Oxygenator with and without integrated Arterial Filter (082117).
Device Description
The Venous Softbag Reservoir is used in extracorporeal circuits during cardiopulmonary bypass surgery and serves as container for a certain blood volume. It consists of plastic foils which are welded together and between which tubes of different diameters and a polyester mesh are sandwiched. The polyester mesh serves for an improved air removal. Application duration: The utilization period of this device is restricted to six hours. The softbag reservoir is delivered sterile and is determined for single use only.
The group of Venous Softbag Reservoirs consists of a variety of models which differ in size (filling volume) and in the port sizes. The filling volumes of the reservoirs range from 650 ml to 1900 ml depending on the model and the ports are either 3/8" or ½" in size.
{1}------------------------------------------------
MAQUET
Statement of Indications for Use
The Venous Softbag Reservoirs are indicated for use in extracorporeal circuits during cardiopulmonary bypass procedures in the field of open-heartsurgery. The utilization period of this device is restricted to six hours. Blood contact longer than 6 hours is not recommended. Application and use of the softbag reservoir is in the sole responsibility of the respective physician.
Statement of Technical Comparison
The Venous Softbag Reservoirs with Softline Coating are identical to the Jostra Venous Softbag Reservoirs with Safeline Coating with the only exception that the Venous Softbag Reservoirs with Softline Coating have been coated with Softline Coating instead of Safeline Coating. However, the Softline Coating is the same as with the QUADROX-i Adult microporous membrane Oxygenator with and without integrated Arterial Filter with Softline Coating. Besides this difference the Venous Softbag Reservoirs with Softline Coating are the same in design, intended use, method of operation, components, packaging, and fundamental scientific technology as compared to the Venous Softbag Reservoirs with Safeline Coating.
Determination of Substantial Equivalence
Evaluation and testing on safety and effectiveness was executed to demonstrate that the Venous Softbag Reservoirs with Softline Coating described in this submission are substantially equivalent to the Jostra Venous Softbag Reservoirs with Safeline Coating as reservoirs and to the QUADROX-i Adult microporous membrane Oxygenator with and without integrated Arterial Filter with Softline Coating regarding the Softline Coating and the pre-assembled combination of the reservoir with the oxygenator.
The following areas have been tested and / or evaluated:
- Integrity -
- Performance .
- Biocompatibility ・
- Sterility -
Conclusion
The data given demonstrate that the Venous Softbag Reservoirs with Softline Coating are substantially equivalent to the named predicate devices which hold currently market clearance.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract symbol resembling a stylized caduceus or a bird-like figure with three wing-like shapes.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room W-O66-0609 Silver Spring, MD 20993-0002
Maquet Cardiopulmonary AG c/o Ms. Katrin Schwenkglenks Hechinger Strasse 38 72145 Hirrlingen Germany
DEC 2 3 2009
Re: K090690
Maquet Venous Softbag Reservoirs with Softline Coating Regulation Number: 21 CFR 870.4400 Regulation Name: Reservoir, Blood, Cardiopulmonary Bypass Regulatory Class: Class II (two) Product Code: DTN Dated: November 23, 2009 Received: November 25, 2009
Dear Mr. Schwenkglenks:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{3}------------------------------------------------
Page 2 - Ms. Katrin Schwenkglenks
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely vours.
W.M.
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications for Use
510(k) Number (if known): _ Kogo 690 Device Name: Venous Softbag Reservoir with Softline Coating __
Indications for Use:
The Venous Softbag Reservoirs are indicated for use in extracorporeal circuits during cardiopulmonary bypass procedures in the field of open-heart-surgery. The utilization period of this device is restricted to six hours. Blood contact longer than 6 hours is not recommended. Application and use of the softbag reservoir is in the sole responsibility of the respective physician.
| Prescription Use (Part 21 CFR 801 Subpart D) | X | AND/OR | Over-The-Counter Use (21 CFR 801 Subpart C) | |
|---|---|---|---|---|
| ---------------------------------------------- | --- | -------- | --------------------------------------------- | -- |
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| (Division Sign-Off) | |
|---|---|
| Division of Cardiovascular Devices | |
| 510(k) Number | K090690 |
| Page | 1 of 1 |
(Posted November 13, 2003)
§ 870.4400 Cardiopulmonary bypass blood reservoir.
(a)
Identification. A cardiopulmonary bypass blood reservoir is a device used in conjunction with short-term extracorporeal circulation devices to hold a reserve supply of blood in the bypass circulation.(b)
Classification. Class II (special controls), except that a reservoir that contains a defoamer or filter is classified into the same class as the defoamer or filter. The device, when it is a cardiopulmonary bypass blood reservoir that does not contain defoamers or blood filters, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.